Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury

Alzheimer's and Dementia

Volumn 10, Issue 1 SUPPL., 2014, Pages

  Greig, Nigel H ^a   Tweedie, David ^a   Rachmany, Lital ^b   Li, Yazhou ^a   Rubovitch, Vardit ^b   Schreiber, Shaul ^b   Chiang, Yung Hsiao ^c,d   Hoffer, Barry J ^e   Miller, Jonathan ^e   Lahiri, Debomoy K ^f   Sambamurti, Kumar ^g   Becker, Robert E ^a,h   Pick, Chaim G ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h Aristea Translational Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CASPASE 9; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOCHROME C; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LIXISENATIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C JUN; PROTEIN KINASE; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CELL SURVIVAL; DENTATE GYRUS; GENE EXPRESSION; GRANULE CELL; HIPPOCAMPUS; HUMAN; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; INCRETINS; NEURONS; RECEPTORS, GLUCAGON;

EID: 84897845269     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.12.011     Document Type: Review

References (184)

1. D.H. Daneshvar, D.O. Riley, C.J. Nowinski, A.C. McKee, R.A. Stern, and R.C. Cantu Long-term consequences: effects on normal development profile after concussion Phys Med Rehabil Clin N Am 22 2011 683 700
2. M. Faul, L. Xu, M. Wald, and V. Coronado Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths, 2002-2006 2010 Centers for Disease Control and Prevention, National Center for Injury Prevention and Control Atlanta, GA
3. M. Susman, S.M. DiRusso, T. Sullivan, D. Risucci, P. Nealon, and S. Cuff et al. Traumatic brain injury in the elderly: increased mortality and worse functional outcome at discharge despite lower injury severity J Trauma 53 2002 219 223
4. C.W. Hoge, D. McGurk, J.L. Thomas, A.L. Cox, C.C. Engel, and C.A. Castro Mild traumatic brain injury in U.S. Soldiers returning from Iraq N Engl J Med 358 2008 453 463
5. H. Terrio, L.A. Brenner, B.J. Ivins, J.M. Cho, K. Helmick, and K. Schwab et al. Traumatic brain injury screening: preliminary findings in a US Army Brigade Combat Team J Head Trauma Rehabil 24 2009 14 23
6. B. Hosek How is deployment to Iraq and Afghanistan affecting U.S. service members and their families? An overview of early RAND research on the topic 2011 RAND Corporation Santa Monica, CA
7. M.E. Hoffer, C. Balaban, M.D. Slade, J.W. Tsao, and B. Hoffer Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study PLoS One 8 2013 e54163
8. J.V. Rosenfeld, A.C. McFarlane, P. Bragge, R.A. Armonda, J.B. Grimes, and G.S. Ling Blast-related traumatic brain injury Lancet Neurol 12 2013 882 893
9. J.L. Duckworth, J. Grimes, and G.S. Ling Pathophysiology of battlefield associated traumatic brain injury Pathophysiology 20 2013 23 30
10. E. Park, J.D. Bell, and A.J. Baker Traumatic brain injury: can the consequences be stopped? CMAJ 178 2008 1163 1170
11. Multi-National Corps-Iraq policy on mild traumatic brain injury, May 6, 2008. http://www.pdhealth.mil/downloads/mTBI-Policy6may.pdf /. Accessed: January 9, 2014.
12. A.I. Maas, N. Stocchetti, and R. Bullock Moderate and severe traumatic brain injury in adults Lancet Neurol 7 2008 728 741
13. G. Barkhoudarian, D.A. Hovda, and C.C. Giza The molecular pathophysiology of concussive brain injury Clin Sports Med 30 2011 33 48
14. C. Cornelius, R. Crupi, V. Calabrese, A. Graziano, P. Milone, and G. Pennisi et al. Traumatic brain injury (TBI): oxidative stress and neuroprotection Antioxid Redox Signal 19 2013 836 853
15. M.W. Greve, and B.J. Zink Pathophysiology of traumatic brain injury Mt Sinai J Med 76 2009 97 104
16. D.W. Choi, M. Mauluccigedde, and A.R. Kriegstein Glutamate neurotoxicity in cortical cell-culture J Neurosci 7 1987 357 368
17. L.E. Goldstein, A.M. Fisher, C.A. Tagge, X.L. Zhang, L. Velisek, and J.A. Sullivan et al. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model Sci Transl Med 4 2012 134ra60
18. R. Raghupathi Cell death mechanisms following traumatic brain injury Brain Pathol 14 2004 215 222
19. R.S. Morrison, Y. Kinoshita, M.D. Johnson, W. Guo, and G.A. Garden p53-dependent cell death signaling in neurons Neurochem Res 28 2003 15 27
20. L.Z. Hong, X.Y. Zhao, and H.L. Zhang p53-mediated neuronal cell death in ischemic brain injury Neurosci Bull 26 2010 232 240
21. V. Tashlykov, Y. Katz, V. Gazit, O. Zohar, S. Schreiber, and CG. Pick Apoptotic changes in the cortex and hippocampus following minimal brain trauma in mice Brain Res 1130 2007 197 205
22. V. Tashlykov, Y. Katz, A. Volkov, V. Gazit, S. Schreiber, and O. Zohar et al. Minimal traumatic brain injury induce apoptotic cell death in mice J Mol Neurosci 37 2009 16 24
23. N. Plesnila, L. von Baumgarten, M. Retiounskaia, D. Engel, A. Ardeshiri, and R. Zimmermann et al. Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappa B transcriptional activity Cell Death Differ 14 2007 1529 1541
24. D. Tweedie, A. Milman, H.W. Holloway, Y. Li, B.K. Harvey, and H. Shen et al. Apoptotic and behavioural consequences of mild brain trauma in mice: markers for prospective intervention J Neurosci Res 85 2007 805 815
25. L. Rachmany, D. Tweedie, V. Rubovitch, Q.S. Yu, Y. Li, and J.Y. Wang et al. Cognitive impairments accompanying rodent mild traumatic brain injury involve p53-dependent neuronal cell death and are ameliorated by the tetrahydrobenzothiazole PFT-α PLoS One 8 2013 e79837
26. B.G. Lyeth, LW. Jenkins, RJ. Hamm, CE. Dixon, LL. Phillips, and G.L. Clifton et al. Prolonged memory impairment in the absence of hippocampal cell death following traumatic brain injury in the rat Brain Res 526 1990 249 258
27. T.K. McIntosh, M. Juhler, and T. Wieloch Novel pharmacologic strategies in the treatment of experimental traumatic brain injury J Neurotrauma 15 1998 731 769
28. R. Raghupathi, D.I. Graham, and T.K. McIntosh Apoptosis after traumatic brain injury J Neurotrauma 17 2000 927 938
29. K.A. Frankola, N.H. Greig, W. Luo, and D. Tweedie Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases CNS Neurol Disord Drug Targets 10 2011 391 403
30. D. Tweedie, K. Sambamurti, and N.H. Greig New TNF-α inhibitors as drug candidates for neurodegenerative diseases Curr Alzheimer Res 4 2007 378 385
31. M.K. McCoy, and M.G. Tansey TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease J Neuroinflamm 5 2008 45
32. T. Woodcock, and M.C. Morganti-Kossmann The role of markers of inflammation in traumatic brain injury Front Neurol 4 2013 18
33. H.S. Levin Cognitive function outcomes after traumatic brain injury Curr Opin Neurol 11 1998 643 646
34. H.M. Bramlett, E.J. Green, and W.D. Dietrich Hippocampally dependent and independent chronic spatial navigational deficits following parasagittal fluid percussion brain injury in the rat Brain Res 762 1997 195 202
35. C.E. Dixon, PM. Kochanek, HQ. Yan, JK. Schiding, RG. Griffith, and E. Baum et al. One-year study of spatial memory performance, brain morphology, and cholinergic markers after moderate controlled cortical impact in rats J Neurotrauma 16 1999 109 122
36. O. Zohar, S. Schreiber, V. Getslev, J.P. Schwartz, P.G. Mullins, and CG. Pick Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice Neuroscience 118 2003 949 955
37. O. Zohar, V. Rubovitch, A. Milman, S. Schreiber, and C.G. Pick Behavioral consequences of minimal traumatic brain injury in mice Acta Neurobiol Exp 71 2011 36 45
38. I.K. Moppett Traumatic brain injury: assessment, resuscitation and early management Br J Anaesth 99 2007 18 31
39. V. Raymont, A.M. Salazar, F. Krueger, and J. Grafman "Studying injured minds" - the Vietnam head injury study and 40 years of brain injury research Front Neurol 2 2011 15
40. N. Marklund, and L. Hillered Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here? Br J Pharmacol 164 2011 1207 1229
41. Y. Xiong, A. Mahmood, and M. Chopp Animal models of traumatic brain injury Nat Rev Neurosci 14 2013 128 142
42. A. Milman, A. Rosenberg, R. Weizman, and C.G. Pick Mild traumatic brain injury induces persistent cognitive deficits and behavioral disturbances in mice J Neurotrauma 22 2005 1003 1010
43. R. Hicks, H. Soares, D. Smith, and T. McIntosh Temporal and spatial characterization of neuronal injury following lateral fluid-percussion brain injury in the rat Acta Neuropathol 91 1996 236 246
44. K.E. Saatman, K.J. Feeko, R.L. Pape, and R. Raghupathi Differential behavioral and histopathological responses to graded cortical impact injury in mice J Neurotrauma 23 2006 1241 1253
45. J. Cheng, J. Gu, Y. Ma, T. Yang, Y. Kuang, and B. Li et al. Development of a rat model for studying blast-induced traumatic brain injury J Neurol Sci 294 2010 23 28
46. M. Risling, S. Plantman, M. Angeria, E. Rostami, B.M. Bellander, and M. Kirkegaard et al. Mechanisms of blast induced brain injuries, experimental studies in rats Neuroimage 54 Suppl. 2011 S89 S97
47. R.D. Readnower, M. Chavko, S. Adeeb, M.D. Conroy, J.R. Pauly, R.M. McCarron, and et al Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury J Neurosci Res 88 2010 3530 3539
48. B.R. Huber, J.S. Meabon, T.J. Martin, P.D. Mourad, R. Bennett, and B.C. Kraemer et al. Blast exposure causes early and persistent aberrant phospho- and cleaved-tau expression in a murine model of mild blast-induced traumatic brain injury J Alzheimers Dis 37 2013 309 323
49. V. Rubovitch, M. Ten-Bosch, O. Zohar, C.R. Harrison, C. Tempel-Brami, E. Stein, and B.J. Hoffer et al. A mouse model of blast-induced mild traumatic brain injury Exp Neurol 232 2011 280 289
50. M.P. Mattson, and T. Magnus Ageing and neuronal vulnerability Nat Rev Neurosci 7 2006 278 294
51. C. Van Den Heuvel, E. Thornton, and R. Vink Traumatic brain injury and Alzheimer's disease: a review Prog Brain Res 161 2007 303 316
52. S. Signoretti, R. Vagnozzi, B. Tavazzi, and G. Lazzarino Biochemical and neurochemical sequelae following mild traumatic brain injury: summary of experimental data and clinical implications Neurosurg Focus 29 2010 E1
53. N.H. Greig, M.P. Mattson, T. Perry, S.L. Chan, T. Giordano, and K. Sambamurti et al. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists Ann NY Acad Sci 1035 2004 290 315
54. Y.K. Kwon Effect of neurotrophic factors on neuronal stem cell death J Biochem Mol Biol 35 2002 87 93
55. Z.Z. Chong, F. Li, and K. Maiese Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury Histol Histopathol 20 2005 299 315
56. P.S. Eriksson, E. Perfilieva, T. Björk-Eriksson, AM. Alborn, C. Nordborg, and DA. Peterson et al. Neurogenesis in the adult human hippocampus Nat Med 4 1998 1313 1317
57. H.G. Kuhn, H. Dickinson-Anson, and H.F. Gage Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation J Neurosci 16 1996 2027 2033
58. R. Rola, S. Mizumatsu, S. Otsuka, D.R. Morhardt, L.J. Noble-Haeusslein, and K. Fishman et al. Alterations in hippocampal neurogenesis following traumatic brain injury in mice Exp Neurol 202 2006 189 199
59. R.M. Richardson, D. Sun, and M.R. Bullock Neurogenesis after traumatic brain injury Neurosurg Clin N Am 18 2007 169 181
60. R.M. Richardson, A. Singh, D. Sun, H.L. Fillmore, D.W. Dietrich 3rd, and M.R. Bullock Stem cell biology in traumatic brain injury: effects of injury and strategies for repair J Neurosurg 112 2010 1125 1138
61. O. Lazarov, and R.A. Marr Of mice and men: neurogenesis, cognition and Alzheimer's disease Front Aging Neurosci 5 2013 43
62. H.A. Cameron, C. Woolley, B.S. McEwen, and E. Gould Differentiation of newly born neurons and glia in the dentate gyrus of the adult rat Neuroscience 56 1993 337 344
63. E.A. Markakis, and F.H. Gage Adult-generated neurons in the dentate gyrus send axonal projections to field CA3 and are surrounded by synaptic vesicles J Comp Neurol 406 1999 449 460
64. C. Zhao, E.M. Teng, R.G. Summers, G. Ming, and F.H. Gage Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus J Neurosci 26 2006 3 11
65. H. van Praag, A.F. Schinder, B. Christie, N. Toni, T.D. Palmer, and F.H. Gage Functional neurogenesis in the adult hippocampus Nature 415 2002 1030 1034
66. C. Vivar, M.C. Potter, J. Choi, J.Y. Lee, T.P. Stringer, and E.M. Callaway et al. Monosynaptic inputs to new neurons in the dentate gyrus Nat Commun 3 2012 1107
67. O. Lazarov, M.P. Mattson, D.A. Peterson, S.W. Pimplikar, and H. van Praag When neurogenesis encounters aging and disease Trends Neurosci 33 2010 569 579
68. T.J. Shors, G. Miesegaes, A. Beylin, M. Zhao, T. Rydel, and E. Gould Neurogenesis in the adult is involved in the formation of trace memories Nature 410 2001 372 376
69. M.L. Monje, H. Toda, and T.D. Palmer Inflammatory blockade restores adult hippocampal neurogenesis Science 302 2003 1760 1765
70. N.P. Whitney, T.M. Eidem, H. Peng, Y. Huang, and J.C. Zheng Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders J Neurochem 108 2009 1343 1359
71. T. Perry, and N.H. Greig The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease J Alzheimers Dis 4 2002 487 496
72. T. Perry, and N.H. Greig The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci 24 2003 377 383
73. T. Perry, and N.H. Greig A new Alzheimer's disease interventive strategy: GLP-1 Curr Drug Targets 5 2004 565 571
74. T. Perry, and N.H. Greig Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease Curr Alzheimer Res 2 2005 377 385
75. I. Salcedo, D. Tweedie, Y. Li, and N.H. Greig Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders Br J Pharmacol 166 2012 1586 1599
76. C. Hölscher The role of GLP-1 in neuronal activity and neurodegeneration Vitam Horm 84 2010 331 354
77. C. Hölscher Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection CNS Drugs 26 2012 871 882
78. E. Mossello, E. Ballini, M. Boncinelli, M. Monami, G. Lonetto, and A.M. Mello et al. Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities Exp Diabetes Res 2011 2011 281674
79. A.I. Duarte, E. Candeias, S.C. Correia, R.X. Santos, C. Carvalho, and S. Cardoso et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration Biochim Biophys Acta 1832 2013 527 541
80. B. Gallwitz Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents Drugs 71 2011 1675 1688
81. J.A. Lovshin, and D.J. Drucker Incretin-based therapies for type 2 diabetes mellitus Nat Rev Endocrinol 5 2009 262 269
82. J.E. Campbell, and D.J. Drucker Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab 17 2013 819 837
83. D.J. Drucker Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls Diabetes 62 2013 3316 3323
84. D.J. Drucker, S.I. Sherman, R.M. Bergenstal, and J.B. Buse The safety of incretin-based therapies - review of the scientific evidence J Clin Endocrinol Metab 96 2011 2027 2031
85. A.M. Habib, P. Richards, L.S. Cairns, G.J. Rogers, C.A. Bannon, and H.E. Parker et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry Endocrinology 153 2012 3054 3065
86. R. Abu-Hamdah, A. Rabiee, G.S. Meneilly, R.P. Shannon, D.K. Andersen, and D. Elahi Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides J Clin Endocrinol Metab 94 2009 1843 1852
87. R.V. Campos, Y.C. Lee, and D.J. Drucker Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse Endocrinology 134 1994 2156 2164
88. J.C. Calvo, C.V. Gisolfi, E. Blazquez, and F. Mora Glucagon-like peptide-1(7-36)amide induces the release of aspartic acid and glutamine by the ventromedial hypothalamus of the conscious rat Brain Res Bull 38 1995 435 439
89. E. Alvarez, I. Roncero, J.A. Chowen, B. Thorens, and E. Blázquez Expression of the glucagon-like peptide-1 receptor gene in rat brain J Neurochem 66 1996 920 927
90. E. Alvarez, M.D. Martínez, I. Roncero, J.A. Chowen, B. García-Cuartero, and J.D. Gispert et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem J Neurochem 92 2005 798 806
91. P.J. Larsen, M. Tang-Christensen, J.J. Holst, and C. Orskov Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem Neuroscience 77 1997 257 270
92. R. Ritzel, C. Orskov, J.J. Holst, and M.A. Nauck Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships Diabetologia 38 1995 720 725
93. N.H. Greig, H.W. Holloway, K.A. De Ore, D. Jani, Y. Wang, and J. Zhou et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations Diabetologia 42 1999 45 50
94. K. De Ore, N.H. Greig, H.W. Halloway, Y. Wang, R. Perfetti, and J.M. Egan The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test J Gerontol B Psychol Sci Soc Sci 52 1997 B245 B249
95. J. Eng, W.A. Kleinman, L. Singh, G. Singh, and J.P. Raufman Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J Biol Chem 267 1992 7402 7405
96. R. Göke, H.C. Fehmann, T. Linn, H. Schmidt, M. Krause, J. Eng, and B. Göke Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells J Biol Chem 268 1993 19650 19655
97. A. Hamilton, and C. Hölscher Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system Neuroreport 20 2009 1161 1166
98. A.J. Kastin, V. Akerstrom, and W. Pan Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier J Mol Neurosci 18 2002 7 14
99. A.J. Kastin, and V. Akerstrom Entry of exendin-4 into brain is rapid but may be limited at high doses Int J Obes Relat Metab Disord 27 2003 313 318
100. W.A. Banks, M.J. During, and M.L. Niehoff Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration J Pharmacol Exp Ther 309 2004 469 475
101. K. Hunter, and C. Hölscher Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis BMC Neurosci 13 2012 33
102. Y. Wang, R. Perfetti, N.H. Greig, H.W. Holloway, K.A. DeOre, and C. Montrose-Rafizadeh et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats J Clin Invest 99 1997 2883 2889
103. M. Szayna, M.E. Doyle, J.A. Betkey, H.W. Holloway, R.G. Spencer, and N.H. Greig et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats Endocrinology 141 2000 1936 1941
104. M.E. Doyle, N.H. Greig, H.W. Holloway, J.A. Betkey, M. Bernier, and J.M. Egan Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent Endocrinology 142 2001 4462 4468
105. M.E. Doyle, M.J. Theodorakis, H.W. Holloway, M. Bernier, N.H. Greig, and J.M. Egan The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity Regul Pept 114 2003 153 158
106. M.E. Doyle, P. McConville, M.J. Theodorakis, M.M. Goetschkes, M. Bernier, and R.G. Spencer et al. In vivo biological activity of exendin (1-30) Endocrine 27 2005 1 9
107. G.S. Meneilly, N. Greig, H. Tildesley, J.F. Habener, J.M. Egan, and D. Elahi Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes Diabetes Care 26 2003 2835 2841
108. G. Xu, D.A. Stoffers, J.F. Habener, and S. Bonner-Weir Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
109. C. Tourrel, D. Bailbé, M.J. Meile, M. Kergoat, and B. Portha Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age Diabetes 50 2001 1562 1570
110. J. Zhou, M.A. Pineyro, X. Wang, M.E. Doyle, and J.M. Egan Exendin-4 differentiation of human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3 transcription factors J Cell Physiol 192 2002 304 314
111. Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis J Biol Chem 278 2003 471 478
112. I.A. Urusova, L. Farilla, H. Hui, E. D'Amico, and R. Perfetti GLP-1 inhibition of pancreatic islet cell apoptosis Trends Endocrinol Metab 15 2004 27 33
113. P.L. Brubaker, and D.J. Drucker Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 145 2004 2653 2659
114. M.R. Walton, and I. Dragunow Is CREB a key to neuronal survival? Trends Neurosci 23 2000 48 53
115. Q. Cui, and K.F. So Involvement of cAMP in neuronal survival and axonal regeneration Anat Sci Int 79 2004 209 212
116. J.H. Yu, and M.S. Kim Molecular mechanisms of appetite regulation Diabetes Metab J 36 2012 391 398
117. M.J. Dailey, and T.H. Moran Glucagon-like peptide 1 and appetite Trends Endocrinol Metab 24 2013 85 91
118. T. Perry, J. Zhou, K. Shaw, D.K. Lahiri, J.M. Egan, and N.H. Greig Induction of differentiation by glucagon-like peptide-1: a novel neurotrophic factor in PC12 cells J Pharmacol Exp Ther 300 2002 958 966
119. T. Perry, N. Haughey, J.M. Egan, and N.H. Greig Amelioration of cholinergic neuron atrophy by glucagon-like peptide-1 J Pharmacol Exp Ther 302 2002 881 888
120. T. Perry, D.K. Lahiri, K. Sambamurti, M.P. Mattson, J.M. Egan, and N.H. Greig A role of glucagon-like peptide-1 in the processing of β-amyloid precursor protein J Neurosci Res 72 2003 603 612
121. C.P. Gilman, T. Perry, K. Furukawa, N.H. Greig, J.M. Egan, and M.P. Mattson Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons J Neurochem 87 2003 1137 1144
122. T.A. Perry, H.W. Holloway, A. Weerasuriya, J.A. Mattison, and N.H. Greig Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy Exp Neurol 203 2007 293 301
123. Y. Li, T. Perry, M.S. Kindy, B.K. Harvey, D. Tweedie, and H.W. Holloway et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism Proc Natl Acad Sci USA 106 2009 1285 1290
124. B. Martin, E. Golden, O.D. Carlson, P. Pistell, J. Zhou, and W. Kim et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease Diabetes 58 2009 318 328
125. Y. Li, K.B. Duffy, M.A. Ottinger, B. Ray, J.A. Bailey, and H.W. Holloway et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease J Alzheimers Dis 19 2010 1205 1219
126. Y. Li, D. Tweedie, M.P. Mattson, H.W. Holloway, and N.H. Greig Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells J Neurochem 113 2010 1621 1631
127. Y. Li, S. Chigurupati, H.W. Holloway, M. Mughal, D. Tweedie, and D.A. Bruestle et al. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis PLoS One 7 2012 e32008
128. R.S. McIntyre, A.M. Powell, O. Kaidanovich-Beilin, J.K. Soczynska, M. Alsuwaidan, and H.O. Woldeyohannes et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders Behav Brain Res 237 2013 164 171
129. A.M. Bak, L. Egefjord, M. Gejl, C. Steffensen, C.W. Stecher, and K. Smidt et al. Targeting amyloid-beta by glucagon-like peptide-1 (GLP-1) in Alzheimer's disease and diabetes Expert Opin Ther Targets 15 2011 1153 1162
130. J.J. Holst, R. Burcelin, and E. Nathanson Neuroprotective properties of GLP-1: theoretical and practical applications Curr Med Res Opin 27 2011 547 558
131. C. Hölscher, and L. Li New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol Aging 31 2010 1495 1502
132. A. Harkavyi, and P.S. Whitton Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection Br J Pharmacol 159 2010 495 501
133. V.A. Gault, and C. Hölscher GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid Eur J Pharmacol 587 2008 112 117
134. X.H. Wang, L. Li, C. Hölscher, Y.F. Pan, X.R. Chen, and J.S. Qi Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats Neuroscience 170 2010 1239 1248
135. P.M. Klinge, K. Harmening, M.C. Miller, A. Heile, C. Wallrapp, and P. Geigle et al. Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease Neurosci Lett 497 2011 6 10
136. P.L. McClean, V. Parthsarathy, E. Faivre, and C. Hölscher The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease J Neurosci 31 2011 6587 6594
137. T.R. Bomfim, L. Forny-Germano, L.B. Sathler, J. Brito-Moreira, J.C. Houzel, and H. Decker et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers J Clin Invest 122 2012 1339 1353
138. K. Talbot, H.Y. Wang, H. Kazi, L.Y. Han, K.P. Bakshi, and A. Stucky et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline J Clin Invest 122 2012 1316 1338
139. W.N. Han, C. Hölscher, L. Yuan, W. Yang, X.H. Wang, and M.N. Wu et al. Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats Neurobiol Aging 34 2013 576 588
140. C.M. Long-Smith, S. Manning, P.L. McClean, M.F. Coakley, D.J. O'Halloran, and C. Hölscher et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease Neuromolecular Med 15 2013 102 114
141. 8-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats J Neurosci Res 91 2013 568 577
142. V. Parthsarathy, and C. Hölscher Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model PLoS One 8 2013 e58784
143. Y. Yang, J. Zhang, D. Ma, M. Zhang, S. Hu, S. Shao, and C.X. Gong Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 Diabetes J Alzheimers Dis 37 2013 637 648
144. P.L. McClean, and C. Hölscher Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease Neuropharmacology 76 2014 57 67
145. H. Xiong, C. Zheng, J. Wang, J. Song, G. Zhao, and H. Shen et al. The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice J Alzheimers Dis 37 2013 623 635
146. J.G. Lim, J.J. Lee, S.H. Park, J.H. Park, S.J. Kim, and H.C. Cho et al. Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement Neurosci Lett 479 2010 13 17
147. W.J. Liu, H.Y. Jin, K.A. Lee, S.H. Xie, H.S. Baek, and T.S. Park Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats Br J Pharmacol 164 2011 1410 1420
148. C.G. Jolivalt, M. Fineman, C.F. Deacon, R.D. Carr, and N.A. Calcutt GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice Diabetes Obes Metab 13 2011 990 1000
149. T. Himeno, H. Kamiya, K. Naruse, N. Harada, N. Ozaki, and Y. Seino et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice Diabetes 60 2011 2397 2406
150. C.H. Lee, B. Yan, K.Y. Yoo, J.H. Choi, S.H. Kwon, and S. Her et al. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia J Neurosci Res 89 2011 1103 1113
151. S. Teramoto, N. Miyamoto, K. Yatomi, Y. Tanaka, H. Oishi, and H. Arai et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia J Cereb Blood Flow Metab 31 2011 1696 1705
152. S. Briyal, K. Gulati, and A. Gulati Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats Brain Res 1427 2012 23 34
153. V. Darsalia, S. Mansouri, H. Ortsäter, A. Olverling, N. Nozadze, and C. Kappe et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats Clin Sci (Lond) 122 2012 473 483
154. M.D. Wang, Y. Huang, G.P. Zhang, L. Mao, Y.P. Xia, and Y.W. Mei et al. Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway Neuroscience 226 2012 388 396
155. G. Bertilsson, C. Patrone, O. Zachrisson, A. Andersson, K. Dannaeus, and J. Heidrich et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease J Neurosci Res 86 2008 326 338
156. A. Harkavyi, A. Abuirmeileh, R. Lever, A.E. Kingsbury, C.S. Biggs, and P.S. Whitton Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease J Neuroinflamm 5 2008 19
157. S. Kim, M. Moon, and S. Park Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease J Endocrinol 202 2009 431 439
158. I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, P. Ell, and T. Soderlund et al. Exenatide and the treatment of patients with Parkinson's disease J Clin Invest 123 2013 2730 2736
159. S. Knippenberg, N. Thau, R. Dengler, T. Brinker, and S. Petri Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS PLoS One 7 2012 e36857
160. H. Sun, S. Knippenberg, N. Thau, D. Ragancokova, S. Körner, and D. Huang et al. Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice Cell Mol Neurobiol 33 2013 347 357
161. M.J. During, L. Cao, D.S. Zuzga, J.S. Francis, H.L. Fitzsimons, and X. Jiao et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection Nat Med 9 2003 1173 1179
162. A. Prakash, and B.F. Matta Hyperglycaemia and neurological injury Curr Opin Anaesthesiol 21 2008 565 569
163. S. Muehlschlegel, R. Carandang, C. Ouillette, W. Hall, F. Anderson, and R. Goldberg Frequency and impact of intensive care unit complications on moderate-severe traumatic brain injury: early results of the Outcome
164. R.L. Smith, J.C. Lin, P.D. Adelson, P.M. Kochanek, E.L. Fink, and S.R. Wisniewski et al. Relationship between hyperglycemia and outcome in children with severe traumatic brain injury Pediatr Crit Care Med 13 2012 85 91
165. W. Pan, A.J. Kastin, T. Rigai, R. McLay, and C.G. Pick Increased hippocampal uptake of tumor necrosis factor alpha and behavioral changes in mice Exp Brain Res 149 2003 195 199
166. L. Rachmany, D. Tweedie, Y. Li, V. Rubovitch, H.W. Holloway, and J. Miller et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice Age 35 2013 1621 1636
167. D. Tweedie, L. Rachmany, V. Rubovitch, E. Lehrmann, Y. Zhang, and K.G. Becker et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice Exp Neurol 239 2013 170 182
168. R. Baratz, D. Tweedie, V. Rubovitch, W. Luo, J.S. Yoon, and BJ. Hoffer et al. Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice J Neurochem 118 2010 1032 1042
169. J.N. Saykally, L. Rachmany, H. Hatic, A. Shaer, V. Rubovitch, and C.G. Pick et al. The nuclear factor erythroid 2-like 2 activator, tert-butylhydroquinone, improves cognitive performance in mice after mild traumatic brain injury Neuroscience 223 2012 305 314
170. D. Tweedie, L. Rachmany, V. Rubovitch, Y. Zhang, K.G. Becker, and E. Perez et al. Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury Neurobiol Dis 54 2013 1 11
171. K.R. Walker, and G. Tesco Molecular mechanisms of cognitive dysfunction following traumatic brain injury Front Aging Neurosci 5 2013 29
172. C.E. Dixon, J.W. Lighthall, and T.E. Anderson Physiologic, histopathologic, and cineradiographic characterization of a new fluid-percussion model of experimental brain injury in the rat J. Neurotrauma 5 1988 91 104
173. C.E. Dixon, B.G. Lyeth, J.T. Povlishock, R.L. Findling, R.J. Hamm, and A. Marmarou et al. A fluid percussion model of experimental brain injury in the rat J. Neurosurg 67 1987 110 119
174. R.J. Hamm, B.G. Lyeth, L.W. Jenkin, D.M. O'Dell, and B.R. Pike Selective cognitive impairment following traumatic brain injury in rats Behav Brain Res 59 1993 169 173
175. K. Eakin, and J.P. Miller Mild traumatic brain injury is associated with impaired hippocampal spatiotemporal representation in the absence of histological changes J Neurotrauma 29 2012 1180 1187
176. K. Eakin, Y. Li, Y.-H. Chiang, B.J. Hoffer, N.H. Greig, and J.P. Miller Exendin-4 reduces brain injury in rats PLoS One 8 2013 e82016
177. A.M. Heile, C. Wallrapp, P.M. Klinge, A. Samii, M. Kassem, and G. Silverberg et al. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury Neurosci Lett 463 2009 176 181
178. A. Heile, and T. Brinker Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1 Dialogues Clin Neurosci 13 2011 279 286
179. I. Hadjiyanni, K.A. Siminovitch, J.S. Danska, and D.J. Drucker Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells Diabetologia 53 2010 730 740
180. A.E. Hogan, A.M. Tobin, T. Ahern, M.A. Corrigan, G. Gaoatswe, and R. Jackson et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis Diabetologia 54 2011 2745 2754
181. N. Panjwani, E.E. Mulvihill, C. Longuet, B. Yusta, J.E. Campbell, and T.J. Brown et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice Endocrinology 154 2013 127 139
182. J.A. Chowen, F.R. de Fonseca, E. Alvarez, M. Navarro, L.M. García-Segura, and E. Blázquez Increased glucagon-like peptide-1 receptor expression in glia after mechanical lesion of the rat brain Neuropeptides 33 1999 212 215
183. R.E. Becker, N.H. Greig, E. Giacobini, L.S. Schneider, and L. Ferrucci A new roadmap for drug development for Alzheimer's disease Nat Rev Drug Discov 2013
184. R.E. Becker, and N.H. Greig Lost in translation: neuropsychiatric drug development Sci Transl Med 2 2010 61rv6